Redcare Pharmacy: Raised Guidance, Peak Growth Behind, but Profitability Inflection Ahead

Europe's leading online pharmacy lifts 2026 outlook on broad-based momentum, but flags deceleration and competition.

RDC.DE · Earnings Call · 2026-07-29

The Second Quarter That Changed the Script

Redcare Pharmacy's Q2 2026 report was not just another beat-and-raise quarter. It was the moment the company pulled back the curtain on its playbook: raising guidance, disclosing marketing details for the first time, and confirming that the explosive Rx growth is now a base-effect story rather than acceleration. Total revenue grew 20% year-over-year, up from 18% in Q1, and the company lifted its full-year revenue and EBITDA margin guidance. But management was equally explicit that July trading has already softened. CEO Olaf Heinrich said: “Total revenue growth, we moved the range up to 15%-17%, from 13%-15% back in March.” — Olaf Heinrich · 2026-07-29 Yet CFO Hendrik Krampe warned in the same breath, “July trading has been soft. We expect group growth below 20% for July.” — Hendrik Krampe · 2026-07-29 This tension between a strong Q2 and an immediate deceleration sets the stage for a nuanced investment narrative. The company’s core thesis remains intact: Germany is the growth engine, and regulation is turning favorable. The fixed dispensing fee (Fixum) is rising, and the pharmacy rebate increase is a partial offset. Critically, the regulation on pharmacy operations, pending final approval, confirms that logistics providers are not burdened with pharmacy obligations — boosting legal certainty for online pharmacies. Management called this a "great regulatory framework" for the franchise. The RX growth in Germany hit 58% in Q2, but as Heinrich explained, this is a technical artifact: "Please do not forget, from September on, we will face also month compared to previous years where we already offered a bonus." “Please do not forget, from September on, we will face also month compared to previous years where we already offered a bonus.” — Olaf Heinrich · 2026-07-29

Profitability Inflection, Not Just Growth

The most striking financial development is the margin expansion. Adjusted EBITDA margin rose 0.9 percentage points to 3.5% in Q2 — the highest in a decade. Hendrik Krampe called it out:

Our adjusted EBITDA margin increased 0.9 percentage points to 3.5% in Q2, and this is the highest EBITDA margin we've delivered in 10 years.
Hendrik Krampe · 2026-07-29

This is driven by disciplined marketing: they've trimmed marketing spend as a percentage of revenue, now targeting ~5%, and they've begun to share details for the first time. The company also touted AI-driven price optimization in Germany, and the international segment reached break-even — a key milestone. But there are cost headwinds: the automation project in Sevenum will consume ~EUR 30 million in H2, and the new personal-signature requirement for prescription delivery adds a small but real cost. Hendrik noted, "It's included in our forecast. It's on an annual base, less than EUR 1 million." “It's included in our forecast. It's on an annual base, less than EUR 1 million.” — Hendrik Krampe · 2026-07-29

Growth Sustainability: Customer Acquisition and Competition

The market is asking how sustainable this growth is. Active customers reached 14.7 million, but the pace of Rx customer adds is slowing, and management admits the key challenge is customer acquisition. Heinrich said, "When we talk about active customers, that is not identical to new customers." “When we talk about active customers, that is not identical to new customers.” — Olaf Heinrich · 2026-07-29 The company is shifting marketing mix toward online acquisition, but the deceleration is structural as the base builds. Competition looms: Rossmann has announced plans to launch an online pharmacy, and DM has already entered. Management downplays the risk, citing complexity, but the threat is real. Jan Koch from Deutsche Bank raised it directly, and Heinrich responded, "It is somehow obviously not so easy to enter our market." “It is somehow obviously not so easy to enter our market.” — Olaf Heinrich · 2026-07-29 The company's high NPS (77 for Rx) and stickiness provide a moat, but the market is watching.

International and the Road Ahead

International grew 17% and is now break-even. The Switzerland joint venture with Galenica is positioned for potential regulatory changes around e-prescriptions and OTC mail delivery. Management is confident in its partnership, but the timeline is uncertain. The company also announced it will merge its revenue and profit updates to one publication per quarter — a move to simplify communications. Given the July softness, the market will be laser-focused on H2 execution. The raised guidance implies confidence, but the decelerating Rx curve and the investment in automation suggest a temporary plateau. Notably, Redcare’s narrative is almost entirely a European one. Unlike the global chatter on tariffs and supply chain reshuffling that dominates earnings season, this call focused on the minutiae of German pharmacy regulation and customer migration. That contrast is a reminder that sector-specific tailwinds can be more durable than macro noise. In summary, Redcare Pharmacy is at an inflection point: margin expansion is real, but growth is normalizing. The stock's reaction will depend on whether investors see the margin story as durable and the growth deceleration as manageable. The company's strategy is clear: optimize profitability while defending its leadership in German online pharmacy.